(New Orleans) ‒ Fluence Analytics, a manufacturer of industrial and laboratory analytics products, today announced it has signed a distribution agreement with Nihon Rufuto, a Japanese company specializing in the import and domestic sales of scientific instruments.
Nihon Rufuto will introduce, market and distribute ARGEN throughout Japan. ARGEN is a static light scattering instrument that yields realtime measurements on the stability of therapeutic proteins and peptides and the quality of natural and synthetic polymers.
The partnership combines ARGEN’s unique technology and the value it delivers to the biopharmaceutical development process with Nihon Rufuto’s presence and expertise in the rapidly expanding Japanese biotech market. Nihon Rufuto is scheduled to showcase an ARGEN system during InterPhex Japan in Tokyo on June 27-29, 2018.
“We are excited about this new partnership enabling us to expand into another major market,” says Alex Reed, CEO of Fluence Analytics. “Working with Nihon Rufuto gives us access to Japan’s diverse range of advanced industries, including polymers and biopharmaceuticals, where our products will help scientists and engineers save time while developing better, safer products.”
About Fluence Analytics
Fluence Analytics is a manufacturer of industrial and laboratory products that produce continuous data streams. These measurements, combined with powerful, proprietary analytical tools, enable realtime optimization of process control and faster R&D for polymer and biopharmaceutical manufacturers. Visit www.FluenceAnalytics.com to learn more about the company’s solutions for realtime data. realtime optimization.
About Nihon Rufuto
Nihon Rufuto is a company concerned with the import and domestic sales of foreign-based medical and scientific instruments. Since 1998 Nihon Rufuto has been engaged in the consulting, marketing and distribution of scientific equipment for R&D and quality control applications in industry and academia. Visit www.nihon-rufuto.com/english/ to know more about the company’s products and applications.
Talaria Antibodies Inc, a spin-off company from LaCell LLC, was a semi-finalist in the Delta I-Fund Demo Day competition. Dr. Shawna Wicks, President and CEO of Talaria Antibodies, and her team completed the twelve week program which included customer discovery interviews with over 70 potential clients and product users. Talaria Antibodies, which was founded to produce polyclonal antibodies for the regenerative medicine and obesity research community, discovered an unmet need for its antibody based products as experimental teaching kits for the high school, junior college and undergraduate classroom. The Delta I-Fund is an early stage, proof-of-concept accelerator formed to train entrepreneurs in the eight-state Delta Regional Authority territory.
Zenopharm, a Xavier University spin-out led by Dr. Guangdi Wang, was recently awarded a $2 Million SBIR Phase II Grant from the National Cancer Institute. Zenopharm was founded in 2012 to commercialize improved endocrine therapeutics for breast cancer, based on the Company’s patent-pending high-bioavailability platform technology. Zenopharm has developed four oncology drug candidates for treatment of hormone receptor positive breast cancer, which are at various preclinical development stages. The SBIR process is very competitive, and Dr. Wang’s success is a great example of the high-quality research being done in Louisiana.
BioAesthetics, a company transforming plastic and reconstructive surgeries through regenerative medicine, closed a financing round led by Silicon Valley-based Hemi Ventures. Investors included San Francisco’s IndieBio, the New Orleans BioFund, and the New Orleans Startup Fund.
“We’re tremendously excited to join the BioAesthetics team on their journey to innovate patient care through regenerative medicine,” said Amy Gu, Managing Director of Hemi Ventures. “Their advancements are writing the next chapter for living tissue grafts and will improve choices for patients and their medical providers.”
This funding accelerates the development of BioAesthetics’ first product – an acellular tissue-engineered graft that regenerates the nipple-areolar complex (NAC) for breast cancer/mastectomy patients who are currently limited to prostheses, tattoos, and surgical reconstructions out of skin. Just like breast reconstruction, NAC reconstruction provides significant physical and psychological benefits for many patients. “Nipple reconstructions are an important part of completing the reconstruction of the breast, but current methods for reconstruction lack in aesthetics and longevity and are unsatisfactory,” said Abigail Chaffin, MD, a reconstructive surgeon at Tulane University. “The NAC graft BioAesthetics offers will be a game-changer in nipple reconstruction.”
Nicholas Pashos, PhD, founder and CEO of BioAesthetics, developed a graft that regenerates a permanent, living NAC during his doctoral work at Tulane University. Test grafts show promising results. Within one week, living cells migrate from the host tissue into and throughout the graft. Within three weeks, blood vessels begin to form within the graft and new skin forms over the graft. These results indicate integration and acceptance of the acellular graft by the host without immunocompromising antibiotics or steroids as is the case with standard organ transplants and tissue grafts. “We’re working hard with reconstructive surgeons to develop innovative treatment options that improve the aesthetic and overall health outcomes for patients,” said Dr. Pashos.